Sanofi Said to Weigh Actelion Bid Challenging J&J

The transcript discusses Johnson & Johnson's (J&J) potential acquisition of Actelion, highlighting the ongoing negotiations and the interest of other potential buyers. Actelion's leadership has shown resistance to selling, complicating the deal. Financial aspects, including the proposed $250 per share offer, are analyzed, with J&J's financial strength noted. The potential involvement of other pharmaceutical companies like Roche is considered, while regulatory and political factors, such as changes in U.S. administration, are also discussed.

What is one reason Actelion's leadership might resist selling the company?

• They plan to merge with another company.

• They want to expand into new markets.

• They have a strong emotional attachment to the company.

• They are waiting for a higher offer.

What is the reported offer price that Johnson & Johnson is willing to pay for Actelion?

• $300

• $250

• $350

• $200

Why might the acquisition of Actelion be challenging for other companies to outbid Johnson & Johnson?

• Actelion has exclusive contracts with J&J.

• J&J has significant financial resources.

• Other companies are not interested in Actelion.

• J&J has already completed the acquisition.

Which company is mentioned as a potential competitor in acquiring Actelion?

• Novartis

• Roche

• Pfizer

• Merck

How might political changes in the US affect the acquisition deal?

• They could lead to stricter regulations.

• They could allow for easier repatriation of funds.

• They could increase competition from local companies.

• They could result in higher taxes for J&J.